Next Article in Journal
Publishing in the Age of the Digital Doctor
Previous Article in Journal
Current Management of Castrate-Resistant Prostate Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue s2
10.3747/co.v17i0.702
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Research in Castration-Resistant Rostate Cancer: What Does the Future Hold?

by
R. J. Macfarlane
1,* and
K. N. Chi
1,2
1
Division of Medical Oncology, BC Cancer Agency–Vancouver Cancer Centre, Vancouver, BC V5Z 4E6, Canada
2
Department of Medicine and Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(s2), 80-86; https://doi.org/10.3747/co.v17i0.702
Submission received: 3 June 2010 / Revised: 2 July 2010 / Accepted: 4 August 2010 / Published: 1 September 2010

Abstract

Prostate cancer (PCa) is the most common non-skin cancer diagnosed in North America, and it affects 1 in 6 men. Patients with recurrent or metastatic PCa will inevitably develop castration-resistant disease after an initial period of hormone responsiveness. The standard first-line treatment for men with castration-resistant PCa (CRPC) is docetaxel, but further treatment options are limited. This review summarizes the research being conducted in CRPC, with specific regard to immunotherapy and to novel targeted therapies directed against the androgen axis, vascular endothelial growth factor, chaperone proteins, the phosphoinositide 3 kinase/Akt/phosphatase and tensin homolog/mammalian target of rapamycin pathway, and endothelin-1.
Keywords: castration-resistant prostate cancer; novel therapy; targeted therapy castration-resistant prostate cancer; novel therapy; targeted therapy

Share and Cite

MDPI and ACS Style

Macfarlane, R.J.; Chi, K.N. Research in Castration-Resistant Rostate Cancer: What Does the Future Hold? Curr. Oncol. 2010, 17, 80-86. https://doi.org/10.3747/co.v17i0.702

AMA Style

Macfarlane RJ, Chi KN. Research in Castration-Resistant Rostate Cancer: What Does the Future Hold? Current Oncology. 2010; 17(s2):80-86. https://doi.org/10.3747/co.v17i0.702

Chicago/Turabian Style

Macfarlane, R. J., and K. N. Chi. 2010. "Research in Castration-Resistant Rostate Cancer: What Does the Future Hold?" Current Oncology 17, no. s2: 80-86. https://doi.org/10.3747/co.v17i0.702

APA Style

Macfarlane, R. J., & Chi, K. N. (2010). Research in Castration-Resistant Rostate Cancer: What Does the Future Hold? Current Oncology, 17(s2), 80-86. https://doi.org/10.3747/co.v17i0.702

Article Metrics

Back to TopTop